NSEChange in Director(s)13 Jul 2026 · 13 Jul 2026, 05:37 pm
Change in Director(s)
Sun Pharma Advanced Research Company Limited · SPARC
✦ AI SummaryMgmt Change
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Change in Director(s) of the company. Dr. Rajamannar Thennati retires from the Board of Directors upon completion of his term, and Mr. Anil Raghavan is appointed as Managing Director and Chief Executive Officer with effect from August 11, 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst6/10
Governance Concern2/10
Regulatory Risk1/10
Balance Sheet Risk4/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Change in Director(s) of the company.
Attachments (1)
📄pdf
Download →
SPARC_13072026173744_Reg30Intimation13072026.pdf
View document text
SPARC/Sec/SE/2026-27/20 July 13, 2026
National Stock Exchange of India Ltd., BSE Limited,
Exchange Plaza, 5th Floor, Market Operations Dept.
Plot No. C/1, G Block, P. J. Towers,
Bandra Kurla Complex, Dalal Street,
Bandra (East), Mumbai – 400 051. Mumbai - 400 001.
Scrip Symbol: SPARC Scrip Code: 532872
Dear Sir/Madam,
Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)
Pursuant to Regulation 30 read with Schedule III of SEBI Listing Regulations, we wish to
inform you, the Board of Directors of the Company has considered and approved the
following:
1. Dr. Rajamannar Thennati (DIN: 001415412) retires from the Board of Directors of the
Company upon completion of his term as a Director at the ensuing 21st Annual General
Meeting i.e., August 10, 2026.
2. Appointment of Mr. Anil Raghavan (DIN: 03548731), Chief Executive Officer (CEO) of the
Company as Managing Director and Chief Executive Officer of the Company with effect
from August 11, 2026 and liable to retire by rotation, subject to the approval of members
at the ensuing 21st Annual General Meeting of the Company.
Mr. Anil Raghavan is not related to any other director of the Company and is not debarred
from holding the office of director by any SEBI order or any other authority
Details required under Regulation 30 read with Para A of Schedule III (Part A) of SEBI Listing
Regulations, along with the additional details required pursuant to SEBI Circular No.
SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed herewith as
Annexure - A.
You are requested to take the above information on record.
For Sun Pharma Advanced Research Company Limited
Kajal Damania
Company Secretary and Compliance Officer
Encl: As above
Annexure A
Disclosures required under Regulation 30 read with Para A of Schedule Ill (Part A) of SEBI
Listing Regulations, along with the additional details required under the SEBI Listing
Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November
11, 2024.
Sr. Particulars Details of Senior Management Personnel
No Mr. Anil Raghavan Dr. Rajamannar Thennati
1 Reason for change viz. Appointment Retirement
appointment, re-
appointment, resignation,
removal, death
or otherwise
2 Date of appointment/re- August 11, 2026 August 10, 2026
appointment/ cessation (as
applicable) & term of
appointment/re-
appointment
3 Brief profile (in case of Mr. Anil Raghavan currently Not Applicable
appointment) serves as the Chief Executive
Officer of Sun Pharma
Advanced Research Company
Limited (SPARC). Anil is
responsible for developing
and executing strategies to
realize SPARC’s vision of
becoming a Global
Pharmaceutical Leader with a
portfolio of innovative
solutions. He operates from
SPARC’s Mumbai office.
Mr. Anil also serves as a
mentor of an early stage
Machine Learning company,
AIRAMATRIX Private
Limited which focuses on the
application of high content
image processing and deep
learning to transform drug
development and clinical
practice.
Anil spent a decade
consulting with leading firms
such as Arthur Andersen,
KPMG and Cambridge
Technology Partners before
joining Quintiles. He helped
the leadership teams of
several companies in
developing and evaluating
business strategy, and
improving business
performance. Anil served
customers in varied segments
like Media and Entertainment,
Telecommunications, Health
Care services, and
Technology/Outsourcing.
Anil substantially contributed
to developing consulting
solutions for the emerging
Information Technology and
Business Process Outsourcing
industries.
Anil is an Industrial Engineer
with a deep interest in
evolving science and
technologies in
pharmaceutical R&D and
health care delivery segments.
An active speaker at events, he
has participated in several
industry sector studies,
working with business lobbies
and industry associations to
highlight sectoral
opportunities and challenges.
4 Disclosure of Relationship Mr. Anil Raghavan is not Not Applicable
between Directors (in case related to any director of the
of appointment of a Company.
Director)
For Sun Pharma Advanced Research Company Limited
Kajal Damania
Company Secretary and Compliance Officer